Senaste försöken


EudraCT Number: 2022-001876-32 Sponsor Protocol Number: SLN360-002 Start Date: 2023-04-14
Sponsor Name: Silence Therapeutics plc
Full Title: A multi-centre, randomised, double-blind placebo-controlled, Phase 2 study to investigate efficacy, safety and tolerability of SLN360 in participants with elevated lipoprotein(a) at high risk of at...
Medical condition: elevated lipoprotein (a) and high risk of atherosclerotic cardiovascular disease (ASCVD) events
Disease: Version SOC Term Classification Code Term Level
21.1 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
20.0 10022891 - Investigations 10054009 Lipoprotein (a) increased PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: ES (Ongoing) NL (Ongoing) SK (Ongoing) DK (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-000788-30 Sponsor Protocol Number: 1.2022 Start Date: 2023-04-13
Sponsor Name: Uzdrowisko Kamień Pomorski S.A.
Full Title: Evaluation of the effectiveness of Methocarbamol in the treatment of spasticity in people with spinal cord injury.
Medical condition:
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: PL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2020-001181-10 Sponsor Protocol Number: P003077 Start Date: 2023-04-13
Sponsor Name: Medical Center - University of Freiburg
Full Title: Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – a rand...
Medical condition: Primary diffuse large B-cell lymphoma of the central nervous system (PCNSL) is a rare lymphoma affecting only the central nervous system compartment. PCNSL patients are typically 60 years or older ...
Disease: Version SOC Term Classification Code Term Level
Population Age: Elderly Gender: Male, Female
Trial protocol: AT (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-001393-58 Sponsor Protocol Number: T21-118 Start Date: 2023-04-13
Sponsor Name: Hagaziekenhuis
Full Title: POMPAE trial: Peri-Operative Magnesium infusion to Prevent Atrial fibrillation Evaluated.
Medical condition: Atrial fibrillation
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: NL (Prematurely Ended)
Trial results: (No results available)
EudraCT Number: 2022-001297-63 Sponsor Protocol Number: ML-ORI-201 Start Date: 2023-04-13
Sponsor Name: Melinta Therapeutics, LLC
Full Title: A Multicenter, Open-Label, Evaluator-Blinded, Randomized Study to Evaluate the Safety and Tolerability of Single-Dose IV Oritavancin Versus Standard of Care for the Treatment of Pediatric Subjects...
Medical condition: Acute Bacterial Skin and Skin Structure Infections
Disease: Version SOC Term Classification Code Term Level
Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
Trial protocol: BG (Ongoing) LT (Ongoing) LV (Ongoing) PL (Ongoing) ES (Ongoing) PT (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-003065-38 Sponsor Protocol Number: 1102-DMD-Pre-CT03 Start Date: 2023-04-13
Sponsor Name: Antisense Therapeutics Limited
Full Title: A multicentre, randomised, double-blind, placebo-controlled and open label extension study to assess the efficacy, safety, and pharmacokinetic profile of two dose levels of ATL1102 administered by ...
Medical condition: Duchenne Muscular Dystrophy
Disease: Version SOC Term Classification Code Term Level
20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
Population Age: Children, Adolescents, Under 18 Gender: Male
Trial protocol: BG (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-002524-12 Sponsor Protocol Number: BNZ-20-01-2022 Start Date: 2023-04-13
Sponsor Name: AZAD Pharma AG
Full Title: A prospective, phase III, multicenter, randomized, investigator-blinded, two-arm, parallel groups, non-inferiority clinical trial for the comparison of efficacy and safety of a preservative-free Br...
Medical condition: GLAUCOMA , OCCULAR HYPERTENSION
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: BG (Prematurely Ended)
Trial results: (No results available)

EudraCT Number: 2022-002014-16 Sponsor Protocol Number: VIR-MHB1-V200 Start Date: 2023-04-12
Sponsor Name: Vir Biotechnology, Inc.
Full Title: A Platform Study Evaluating the Efficacy and Safety of Investigational Therapies in Participants with Chronic Hepatitis B Infection (PREVAIL)
Medical condition: Chronic Hepatitis B Virus (HBV) Infection
Disease: Version SOC Term Classification Code Term Level
20.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
Population Age: Adults Gender: Male, Female
Trial protocol: BG (Prematurely Ended)
Trial results: (No results available)
EudraCT Number: 2022-002751-19 Sponsor Protocol Number: 82160 Start Date: 2023-04-11
Sponsor Name: Amsterdam UMC
Full Title: FAPi-PET imaging of in vivo fibrosis in inflammatory bowel disease patients
Medical condition: Inflammatory Bowel Diseases
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: NL (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-002746-40 Sponsor Protocol Number: VX22-864-108 Start Date: 2023-04-11
Sponsor Name: Vertex Pharmaceuticals Incorporated
Full Title: A Phase 2, Open-label Study Evaluating Efficacy and Safety of VX-864 in Subjects With Alpha-1 Antitrypsin Deficiency Who Have the PiZZ Genotype, Over 48 Weeks
Medical condition: Alpha 1 antitrypsin deficiency in Subjects With the PiZZ Genotype
Disease: Version SOC Term Classification Code Term Level
23.1 10010331 - Congenital, familial and genetic disorders 10083869 Alpha-1 antitrypsin deficiency PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: IE (Prematurely Ended)
Trial results: (No results available)
3